HONG KONG, Dec. 13, 2024 /PRNewswire/ — Heranova, a pioneering company in women’s health, is proud to introduce HerResolve™, a revolutionary non-invasive blood test for the early diagnosis and management of endometriosis, at the 2024 Ovarian Club Asian Conference. The event, taking place on December 14-15 at the Hong Kong Convention and Exhibition Centre, marks a significant milestone in the fight against this challenging condition.
Endometriosis, a prevalent and often debilitating disorder affecting millions of women globally, has long posed diagnostic difficulties. Traditional methods, typically involving invasive procedures, can be uncomfortable and carry risks. HerResolve™ provides a much-needed alternative, offering a simple blood draw with an impressive 92% diagnostic accuracy rate, enabling early detection of endometriosis in women suffering from symptoms like pelvic pain, painful menstruation, or infertility.
The test leverages advanced technology and extensive research into the molecular biology of endometriosis. HerResolve™ identifies key miRNA biomarkers associated with the condition and applies proprietary AI algorithms and bioinformatics to deliver clear “positive/negative” results, providing healthcare professionals with accurate and reliable diagnostic information. This allows for quicker, more effective diagnoses, improving patient outcomes.
“We understand the complexity and urgency of diagnosing endometriosis,” said Dr. Jonathan Zhao, CEO of Heranova. “HerResolve™ represents years of dedicated research and innovation. It will revolutionize how we diagnose and treat this condition, offering earlier and more precise identification, empowering doctors to tailor personalized treatment plans and advancing the field of gynecological medicine.”
Dr. Zhao, along with Dr. Farideh Bischoff, Chief Medical Officer of Diagnostics at Heranova, will present the test’s technological advancements and clinical applications to global experts and attendees at the conference, highlighting the transformative potential of HerResolve™ in the fight against endometriosis.
Related topics:
Trump Outlines Key Priorities for First 100 Days in Office
Mumbai’s Cama Hospital Introduces PRP Therapy to Boost Ovarian Reserve in Infertility Treatment
